Successful treatment of erosive lichen planus with Upadacitinib complicated by oral squamous cell carcinoma

Author:

Landells Fiona M1ORCID,Goudie Shaina2,McGrath Jerry3,Tibbo Jamie4,Landells Ian DR5

Affiliation:

1. Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NL, Canada

2. Division of Rheumatology, Memorial University of Newfoundland, St. John’s, NL, Canada

3. Division of Gastroenterology, Memorial University of Newfoundland, St. John’s, NL, Canada

4. Division of Otolaryngology, Memorial University of Newfoundland, St. John’s, NL, Canada

5. Division of Dermatology, Memorial University of Newfoundland, St. John’s, NL, Canada

Abstract

Erosive lichen planus is a chronic auto-inflammatory disease which affects the stratified squamous epithelia resulting in painful ulcerations of both the skin and mucosal surfaces, and has a known malignant potential. Management of erosive lichen planus has proven to be difficult; however, recent reports of treatment with Janus kinase inhibitors such as Upadacitinib, are encouraging. This report outlines the third reported case of erosive lichen planus to be successfully treated with Upadacitinib in a 70-year-old woman with treatment-resistant disease. In addition, we report the complication of oral squamous cell carcinoma which became apparent once the extensive erosive lichen planus had healed. This case report highlights the importance of monitoring for mucosal squamous cell carcinoma in areas affected by erosive lichen planus, as squamous cell carcinoma can mimic the erosions of erosive lichen planus.

Publisher

SAGE Publications

Subject

General Medicine

Reference12 articles.

1. JAK inhibitors in lichen planus: a review of pathogenesis and treatments

2. The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders

3. U.S. FDA approves RINVOQ® (upadacitinib) to treat adults and children 12 years and older with refractory, moderate to severe atopic dermatitis. News Center, https://news.abbvie.com/news/press-releases/us-fda-approves-rinvoq-upadacitinib-to-treat-adults-and-children-12-years-and-older-with-refractory-moderate-to-severe-atopic-dermatitis.htm (2022, accessed 19 August 2023).

4. Canada A. AbbVie receives Health Canada approval of RINVOQ® (UPADACITINIB), an oral medication for the treatment of adults with moderate to severe active rheumatoid arthritis. Cision Canada (2020, accessed 19 August 2023).

5. Alleviation of erosive oral and esophageal lichen planus by the JAK1 inhibitor upadacitinib

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Lichen Planus: What is New in Diagnosis and Treatment?;American Journal of Clinical Dermatology;2024-07-09

2. Recalcitrant lichen planopilaris treated with upadacitinib: a case series;International Journal of Dermatology;2024-06-24

3. Multiple drugs;Reactions Weekly;2024-04-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3